ADVISORY BOARD

Former EVP, Head of R&D at CRISPR Therapeutics, built a world class R&D engine and a pipeline of over 10 product candidates including Exa-cel.

Former SVP and Head of Oncology Integration and Innovation at AstraZeneca and oversaw the development and commercialization of Lynparza and Imfinizi (anti-PD-L1).

Former Head of Neurology and Ophthalmology at Merck, former Co-Founder and CSO of Neuronyx.

Successfully repositioned a failed NK3 antagonist for PCOS and won the 2013 AZ Patent of the Year Award.

B.S. in Electrical Engineering at the UCLA, and M.D. from the Johns Hopkins. Assistanted Professor at Johns Hopkins specialized in neuropathy and neuromuscular diseases.

Published widely in several fields with over 80 papers. Co-authored two oncology review articles on oncology drug development and the use of intermediate endpoint.